Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml
Z Gastroenterol 2023; 61(04): 372-374
DOI: 10.1055/a-2026-1182
DOI: 10.1055/a-2026-1182
Editorial
Editorial der S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome
Schlüsselwörter
biliäre Karzinome - Hepatozelluläres Karzinom - Diagnostik - Therapie - Risikofaktoren - HCC - hepatobiliäre Karzinome - Cholangiokarzinome - CCAPublication History
Received: 23 January 2023
Accepted: 02 February 2023
Article published online:
11 April 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Akl EA, Meerpohl JJ, Elliott J. et al. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol 2017; 91: 47-53 DOI: 10.1016/j.jclinepi.2017.08.009.
- 2 AWMF Regelwerk: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. 2020 Verfügbar (Zugriff am 02.12.22): 2. Auflage. http://www.awmf.org/leitlinien/awmf-regelwerk.html
- 3 Krebs in Deutschland für 2017/2018. 13. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin: 2021
- 4 Andant C, Puy H, Bogard C. et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000; 32: 933-939 DOI: 10.1016/s0168-8278(00)80097-5.
- 5 Baravelli CM, Sandberg S, Aarsand AK. et al. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Intern Med 2017; 282: 229-240 DOI: 10.1111/joim.12646.
- 6 de Fost M, Vom Dahl S, Weverling GJ. et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36: 53-58 DOI: 10.1016/j.bcmd.2005.08.004.
- 7 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 DOI: 10.1056/NEJMoa1915745.
- 8 Cheng AL, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76: 862-873 DOI: 10.1016/j.jhep.2021.11.030.
- 9 Galle PR, Finn RS, Qin S. et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. The Lancet Oncology 2021; 22: 991-1001 DOI: 10.1016/s1470-2045(21)00151-0.
- 10 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 DOI: 10.1056/NEJMoa0908721.
- 11 Oh D-Y, Ruth He A, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 2022; 1 DOI: 10.1056/EVIDoa2200015.
- 12 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 2020; 21: 671-684 DOI: 10.1016/s1470-2045(20)30109-1.
- 13 Lamarca A, Palmer DH, Wasan HS. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology 2021; 22: 690-701 DOI: 10.1016/s1470-2045(21)00027-9.
- 14 Valle JW, Kelley RK, Nervi B. et al. Biliary tract cancer. Lancet 2021; 397: 428-444 DOI: 10.1016/S0140-6736(21)00153-7.
- 15 Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. The Lancet Gastroenterology & Hepatology 2021; 6: 956-969 DOI: 10.1016/s2468-1253(21)00171-0.